Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
NCT ID: NCT06954831
Last Updated: 2025-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
82 participants
INTERVENTIONAL
2025-08-28
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
NCT00103181
Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer
NCT00185744
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT01245712
Ultrahypofractionated Whole Breast Radiation Following Chemotherapy
NCT06664892
Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
NCT02186470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the impact of UF-WBI + CB as assessed by patient-reported Global Cosmesis Score (GCS) at 1 year.
SECONDARY OBJECTIVES:
I. To characterize the patient-reported cosmetic appearance of the breast over time, as assessed by GCS.
II. To determine short- and long-term physician-reported cosmetic appearance of the breast, as assessed by GCS.
III. To evaluate the acute and late patient-reported radiation-associated toxicities.
IV. To evaluate the acute and late physician-reported radiation-associated toxicities.
V. To estimate:
Va. 5-year in-breast recurrence; Vb. 5-year distant recurrence; Vc. 5-year disease-free survival (DFS); Vd. 5-year overall survival (OS).
EXPLORATORY OBJECTIVES:
I. To evaluate patient-reported quality-of-life (QoL). II. To evaluate volumetric and dosimetric factors associated with acceptable breast cosmesis.
III. To evaluate volumetric and dosimetric factors associated with acute and late radiation-associated toxicities.
OUTLINE:
Patients undergo UF-WBI with CB once daily (QD) on consecutive business days for up to 5 fractions in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo cone-beam computed tomography (CBCT) prior to each radiation treatment.
After completion of study treatment, patients are followed up at 1 month, 6 months, then annually for up to 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (UF-WBI with CB)
Patients undergo UF-WBI with CB QD on consecutive business days for up to 5 fractions in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CBCT prior to each radiation treatment.
Cone-Beam Computed Tomography
Undergo CBCT
Hypofractionated External Beam Radiation Therapy
Undergo UF-WBI with CB
Questionnaire Administration
Ancillary studies
Radiation Boost
Undergo UF-WBI with CB
Whole Breast Irradiation
Undergo UF-WBI with CB
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cone-Beam Computed Tomography
Undergo CBCT
Hypofractionated External Beam Radiation Therapy
Undergo UF-WBI with CB
Questionnaire Administration
Ancillary studies
Radiation Boost
Undergo UF-WBI with CB
Whole Breast Irradiation
Undergo UF-WBI with CB
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: ≥ 40 years
* Female
* Ability to read and understand English for questionnaires
* Histologically confirmed breast cancer
* Malignancy must be epithelial. Non-epithelial breast malignancies such as lymphoma or sarcoma are not allowed
* Patients must have undergone breast conserving surgery. Re-excision for negative margins is allowed
* Patients must have undergone surgical staging of the axilla (sentinel lymph node biopsy or axillary lymph node dissection)
* Must have at least one-high risk feature that would necessitate a lumpectomy cavity boost by the treating radiation oncologist
* Patient must have physician-reported "Excellent" or "Good" cosmesis post-lumpectomy and prior to radiation therapy based on the 4-point Global Cosmetic Score
* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test
* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
Exclusion Criteria
* Pathologically or clinically involved regional lymph nodes necessitating comprehensive regional nodal irradiation that includes the supraclavicular fossa
* Clinically significant uncontrolled illness
* Stage IV breast cancer
* Diagnosis of Paget's disease of the nipple
* Other prior or active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* Pregnant or breastfeeding
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephanie M Yoon
Role: PRINCIPAL_INVESTIGATOR
City of Hope Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope at Arcadia
Arcadia, California, United States
City of Hope Medical Center
Duarte, California, United States
City of Hope at Irvine Lennar
Irvine, California, United States
City of Hope Antelope Valley
Lancaster, California, United States
City of Hope South Pasadena
South Pasadena, California, United States
City of Hope at South Bay
Torrance, California, United States
City of Hope Upland
Upland, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-02185
Identifier Type: REGISTRY
Identifier Source: secondary_id
23860
Identifier Type: OTHER
Identifier Source: secondary_id
23860
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.